Here we used CRISPR/Cas9 gene-editing to generate loss-of-function deletions in HIF-1α, HIF-2α, or both HIF-1α and HIF-2α in H1299 NSCLC cells. The gene discussed is EPAS1; the disease is non-small cell lung carcinoma.